↑ トップへ ← 戻る

 Drug(薬物リスト) ALL | DrugBank 

   e.g. "Sirolimus", "アダリムマブ"    Synonyms (Drugs) were also searched for.

A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z other

59 / 1,666 drugs found* Show info (disease name, etc.) on mouse-over.
 No.   DrugBank   薬物名(臨床試験情報から抽出)   KEGG DRUG  KEGG GENES  KEGG PATHWAY   指定難病告示番号
 1   Abatacept  27件: Abatacept; Abatacept injection; Bms 188667 (abatacept); Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept (bms-188667); Abatacept (iv); Abatacept + csdmard; Abatacept + methotrexate; Abatacept + vaccines; Abatacept placebo; Abatacept prefilled syringe; Abatacept, rituximab or tocilizumab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Decrease tocilizumab, abatacept; Double-blind abatacept; Intravenous (iv) abatacept; Iv abatacept; Open-label abatacept; Orencia (abatacept); Orencia abatacept; Subcutaneous (sc) abatacept; Subcutaneous abatacept; Subcutaneous(sc) abatacept; Tocilizumab, abatacept; Abatacept subcutaneous; Abatacept sc; Abatacept (aba);   D03203   2件: CD80, CD86   3件: Cell adhesion molecules (CAMs), Intestinal immune network for IgA production, Rheumatoid arthritis   24件:
11,
13,
19,
41,
44,
46,
49,
50,
51,
53,
55,
60,
65,
84,
93,
96,
97,
107,
164,
222,
271,
284,
285,
300
 2   Acetaminophen  8件: Acetaminophen; Acetaminophen tab 650mg; Acetaminophen/paracetamol; Acetaminophen tablets; Paracetamol (acetaminophen); Tramadol hydrochloride + acetaminophen; Oxycodone/acetaminophen; Tramadol /acetaminophen;   D00217   2件: PTGS1, PTGS2   1件: Arachidonic acid metabolism   13件:
3,
6,
13,
34,
35,
46,
49,
51,
70,
86,
231,
256,
271
 3   Adalimumab  51件: Adalimumab; Adalimumab injection [humira]; Adalimumab (ada); Adalimumab (humira); Adalimumab (humira®); Adalimumab (up to 9 months exposure); Adalimumab 40 mg; Adalimumab 40 mg subcutaneous (sc) every other week (eow); Adalimumab 40mg q2w; Adalimumab 80 mg; Adalimumab pfs and pen; Adalimumab with methotrexate; Adalimumab-eu; Adalimumab-pfizer; Anti-tnf therapy (etanercept or adalimumab); Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar product to adalimumab; Double-blind adalimumab; Etanercept or adalimumab; Humira (adalimumab); Humira 40mg solution for injection in pre-filled syringe (adalimumab); Humira® (adalimumab); Infliximab, etanercept, adalimumab; Methotrexate,adalimumab; New formulation adalimumab; Open-label adalimumab; Open-labeladalimumabrescue; Sb5 (proposed biosimilar to adalimumab); Tnf blockers (infliximab, adalimumab, etanercept); Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); Adalimumab (40 mg); Adalimumab (d2e7); Adalimumab 40 mg eow or ew; Adalimumab and infliximab; Adalimumab injection; Adalimumab prn; Anti-tnf:adalimumab (subcutaneus); Application of adalimumab; Azathioprine or adalimumab and infliximab; Db adalimumab 40 mg eow; Db adalimumab 40 mg ew; Fitc-adalimumab; Infliximab and adalimumab; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab, adalimumab, certolizumab pegol; Ol adalimumab 40 mg; Start adalimumab in monotherapy; Treatment with adalimumab; Adalimumab 40 mg sc every other week; Adalimumab, etanercept, golimumab or infliximab; Gp2017 (adalimumab biosimilar);   D02597   1件: TNF   9件: Antigen processing and presentation, Apoptosis, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, Rheumatoid arthritis, TGF-beta signaling pathway   15件:
19,
37,
41,
46,
56,
84,
96,
97,
151,
160,
164,
222,
226,
269,
271
 4   Alendronic acid  1件: Alendronic acid;   D00939
 D07119 
 1件: FDPS   1件: Terpenoid backbone biosynthesis   7件:
19,
41,
46,
50,
271,
274,
299
 5   Apremilast  7件: Apremilast; Apremilast 20 mg; Apremilast 30 mg; Apremilast 30mg; Apremilast (cc-10004); Apremilast tablet 20 mg; Apremilast tablet 30 mg bid;   D08860   4件: PDE4A, PDE4B, PDE4C, PDE4D   2件: Purine metabolism, cAMP signaling pathway   5件:
46,
50,
56,
97,
271
 6   Atorvastatin  9件: Atorvastatin; Interferon beta treatment to add-on atorvastatin treatment; Interferon beta-1b/atorvastatin group; Untreated to atorvastatin treatment; Atorvastatin tablet 20 mg; Atorvastatin 10mg; Atorvastatin 20mg; Lisinopril, losartan, and atorvastatin; Atorvastatin calcium;   D00258
 D00887
 D07474 
 1件: HMGCR   1件: Terpenoid backbone biosynthesis   17件:
13,
46,
49,
51,
58,
63,
79,
84,
88,
93,
96,
160,
222,
225,
265,
271,
299
 7   Benzyl alcohol  0件:   D00077   -   -   3件:
28,
46,
271
 8   Bimekizumab  1件: Bimekizumab;   D11550   2件: IL17A, IL17F   2件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway   3件:
46,
97,
271
 9   Cannabidiol  6件: Cannabidiol; Cannabidiol / dronabinol capsule 5 mg+2,5 mg; Cannabidiol capsule 5 mg; Cannabidiol tablet 10 mg; Cannabidiol (cbd); Cannabidiol oral solution;   D10915   2件: CNR1, CNR2   1件: Neuroactive ligand-receptor interaction   14件:
2,
6,
13,
46,
95,
96,
97,
140,
144,
145,
157,
158,
193,
271
 10   Celecoxib  7件: Celecoxib; Fixed dose combination ciprofloxacin/celecoxib; Celecoxib (celebrex); Celecoxib 200mg capsule; Celecoxib 200 milligrams; Celecoxib 400 milligrams; Celecoxib, celebrex®;   D00567   1件: PTGS2   1件: Arachidonic acid metabolism   9件:
2,
3,
34,
46,
70,
89,
96,
161,
271
 11   Certolizumab pegol  11件: Certolizumab pegol; 99mtc-s-hynic certolizumab pegol; Certolizumab pegol (cdp870, tradename cimzia); Certolizumab pegol (cdp870, tradename cimzia)(prefilled syringes at the dose of 200mg); Certolizumab pegol (czp); Certolizumab pegol + methotrexate (mtx); Certolizumab pegol (cdp870); Certolizumab pegol (rinn); Certolizumab pegol 400 mg; Infliximab, adalimumab, certolizumab pegol; Cimzia certolizumab pegol 200 mg/ml solution for injection;   D03441   1件: TNF   10件: Adipocytokine signaling pathway, Antigen processing and presentation, Apoptosis, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, Rheumatoid arthritis, TGF-beta signaling pathway, Toll-like receptor signaling pathway   6件:
37,
46,
96,
97,
226,
271
 12   Chlorine  0件:   -   -   -   2件:
46,
271
 13   Diclofenac  9件: Diclofenac; Diclofenac sodium topical gel; Diclofenac sodium; Comparator: diclofenac; Comparator: diclofenac sodium; Diclofenac + omeprazole; Diclofenac natrium pch retard tablet mga 75mg; Diclofenac 50 milligrams; Diclofenac sr;   D00903
 D00904
 D07816 
 2件: PTGS1, PTGS2   1件: Arachidonic acid metabolism   4件:
13,
34,
46,
271
 14   Dronabinol  4件: Dronabinol; Cannabidiol / dronabinol capsule 5 mg+2,5 mg; Dronabinol capsule 2,5 mg; Dronabinol capsule 2.5. mg;   D00306   2件: CNR1, CNR2   1件: Neuroactive ligand-receptor interaction   5件:
2,
13,
46,
271,
298
 15   Entecavir  1件: Entecavir;   D04008
 D07896 
 -   -   5件:
46,
56,
96,
97,
271
 16   Etanercept  39件: Etanercept; Enbrel (etanercept); Etanercept 50 mg solution for injection; 50 mg etanercept; Anti-tnf therapy (etanercept or adalimumab); Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Commercial formulation etanercept; Etanercept (enbrel); Etanercept (enbreltm); Etanercept + methotrexate; Etanercept , methotrexate; Etanercept / autoinjector a; Etanercept 50mg; Etanercept biosimilar; Etanercept liquid; Etanercept or adalimumab; Etanercept pre-filled syringe sq injection; Etanercept treatment; Etanercept via autoinjector a; Etanercept via autoinjector b; Etanercept, other biologics, disease-modifying antirheumatic drugs (dmards), etc; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Methotrexate - etanercept - prednisolone arm; New formulation etanercept; Phase 1: etanercept; Reumatocept (etanercept); Sb4 (etanercept biosimilar); Sb4 (proposed biosimilar to etanercept); Tnf blockers (infliximab, adalimumab, etanercept); Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); Etanercept, methotrexate, prednisolone; Adalimumab, etanercept, golimumab or infliximab; Etanercept (50mg per week); Etanercept (50mg per week, for 2 weeks); Etanercept (50mg per week, for 4 weeks); Etanercept (full-dose); Etanercept (half-dose); Tapering or discontinuation of etanercept;   D00742   2件: LTA, TNF   9件: Adipocytokine signaling pathway, Antigen processing and presentation, Apoptosis, Cytokine-cytokine receptor interaction, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Rheumatoid arthritis, TGF-beta signaling pathway   15件:
15,
28,
35,
38,
39,
46,
50,
53,
56,
60,
85,
228,
271,
285,
298
 17   Etoricoxib  6件: Etoricoxib; Mk0663, etoricoxib; Part i - etoricoxib 60 mg; Part i - etoricoxib 90 mg; Part ii- etoricoxib 60 mg; Part ii- etoricoxib 90 mg;   D03710   1件: PTGS2   1件: Arachidonic acid metabolism   2件:
46,
271
 18   Filgotinib  4件: Filgotinib; Inn - filgotinib; Proposed inn - filgotinib; Propsoed inn - filgotinib;   D10871   1件: JAK1   3件: JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation   6件:
46,
53,
96,
97,
222,
271
 19   Glucosamine  1件: Glucosamine;   D04334   -   -   2件:
46,
271
 20   Golimumab  36件: Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Golimumab; Golimumab 100 mg; Golimumab 100 mg injections; Golimumab 2 mg/kg iv; Golimumab 50 mg; Golimumab 50 mg injections; Golimumab final vialed product (fvp); Golimumab intravenous; Golimumab intravenous (iv); Golimumab liquid in prefilled pen; Golimumab liquid in prefilled syringe; Golimumab liquid in vial; Golimumab pre-filled syringe; Iv golimumab; Sc golimumab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Exposure to golimumab; Golimumab (glm); Golimumab (optimization); Golimumab 1 mg per kg; Golimumab 2 mg per kg; Golimumab 200 mg; Golimumab 4 mg per kg; Golimumab 400 mg; Golimumab 50 mg in patients <80 kg and golimumab 100 mg in patients >80 kg; Golimumab dose 1; Golimumab dose 2; Golimumab prefilled syringe; Golimumab treatment optimization.; Simponi (golimumab); Simponi® (golimumab); Adalimumab, etanercept, golimumab or infliximab; Golimumab (cnto 148); Golimumab injection;   D04358   1件: TNF   9件: Adipocytokine signaling pathway, Apoptosis, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Inflammatory bowel disease (IBD), MAPK signaling pathway, Osteoclast differentiation, Rheumatoid arthritis, TGF-beta signaling pathway   5件:
46,
84,
96,
97,
271
 21   Human interleukin-2  3件: Human interleukin-2; Recombinant human interleukin-2 (rhil-2); Anti-human interleukin-23 monoclonal antibody;   -   -   -   14件:
2,
13,
35,
46,
49,
51,
55,
56,
63,
65,
95,
96,
97,
271
 22   Hydroxychloroquine  16件: Hydroxychloroquine; Hydroxychloroquine sulfate; Leflunomide-sulfasalazine-hydroxychloroquine; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate-sulfasalazine-hydroxychloroquine; Sulphasalazine + hydroxychloroquine or prednisolone; Hydroxychloroquine (z0188); Hydroxychloroquine high; Hydroxychloroquine or chloroquine; Hydroxychloroquine reduced; Versus hydroxychloroquine; Hydroxychloroquine + prednisone; Sirolimus and hydroxychloroquine; Hydroxychloroquine higher dose; Hydroxychloroquine lower dose; Hydroxychloroquine sulphate;   D08050   -   -   18件:
13,
41,
46,
48,
49,
53,
56,
66,
84,
89,
90,
96,
222,
234,
254,
271,
298,
299
 23   Ibuprofen  5件: Ibuprofen; Rebif new formulation + ibuprofen prn; Rebif new formulation + prophylactic ibuprofen; Ibuprofen pch tablet 600mg; Ibuprofen 200mg;   D00126
 D01122
 D04490
 D06606 
 2件: PTGS1, PTGS2   1件: Arachidonic acid metabolism   6件:
13,
46,
65,
113,
271,
299
 24   Iguratimod  2件: Iguratimod; Iguratimod (careram);   D01146   1件: NFKB1   2件: NF-kappa B signaling pathway, Osteoclast differentiation   3件:
46,
53,
271
 25   Imrecoxib  2件: Fengshigutong capsule plus imrecoxib; Imrecoxib;   -   -   -   1件:
271
 26   Indometacin  1件: Indometacin;   D00141
 D01565
 D02110 
 2件: PTGS1, PTGS2   1件: Arachidonic acid metabolism   2件:
225,
271
 27   Infliximab  66件: Infliximab; Infliximab [infliximab biosimilar 3]; Topical infliximab; Remicaide (infliximab); Abp 710 - biosimilar to infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar infliximab; Infliximab (inf) + mtx, db; Infliximab (remicade); Infliximab + methotrexate (mtx); Infliximab 10 mg/kg; Infliximab 3 mg/kg; Infliximab biosimilar; Infliximab control; Infliximab group; Infliximab increased dose; Infliximab increased frequency; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Infliximab, methylprednisolone, methotrexate; Infliximab-eu; Infliximab-pfizer; Innovator infliximab; Methotrexate + infliximab; Remicade (infliximab); Remicade® (infliximab); Remsima (infliximab); Response to infliximab associated with methotrexate; Sb2 (infliximab biosimilar); Sb2 (proposed biosimilar to infliximab); Ta-650 (infliximab); Tnf blockers (infliximab, adalimumab, etanercept); Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); Intravitreal infliximab; 99m technetium infliximab; 99mtc-infliximab; Inflectra (infliximab); Adalimumab and infliximab; Anti tnf therapy including infliximab; Anti-tnf: infliximab (infusion); Azathioprine or adalimumab and infliximab; Ct-p13 sc (infliximab); Infliximab (ifx alone); Infliximab (remicade): 100 mg of lyophilized infliximab; Infliximab 20 mg/kg; Infliximab 5 mg/kg; Infliximab 5 mg/kg body weight infused over 2 hours; Infliximab 5 mg/kg every 6 weeks; Infliximab 7 mg/kg every 8 weeks; Infliximab and adalimumab; Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab infusion; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, adalimumab, certolizumab pegol; Infliximab, azathioprine; Infliximab-biosimilar; Infliximab-innovator; Cyclosporine vs infliximab; Infliximab (ifx); Adalimumab, etanercept, golimumab or infliximab; Infliximab (bcd-055); Infliximab and mtx;   D02598   1件: TNF   9件: Adipocytokine signaling pathway, Antigen processing and presentation, Apoptosis, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), MAPK signaling pathway, Osteoclast differentiation, Rheumatoid arthritis, TGF-beta signaling pathway   23件:
35,
37,
38,
39,
40,
41,
43,
45,
46,
49,
50,
56,
65,
84,
85,
95,
96,
97,
98,
162,
164,
269,
271
 28   Isopropyl alcohol  0件:   D00137   -   -   10件:
13,
46,
58,
84,
96,
97,
269,
271,
279,
298
 29   Ixekizumab  1件: Ixekizumab;   D10071   1件: IL17A   2件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway   4件:
37,
162,
269,
271
 30   Leflunomide  10件: Leflunomide; Leflunomide 10mg tab; Leflunomide (permitted, not necessary); Leflunomide 20 mg tablets (geneva pharmaceutical); Leflunomide 20mg tab; Leflunomide-sulfasalazine-hydroxychloroquine; Non-mtx dmards (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin); Leflunomide mylan; Leflunomide 20 mg+prednisone 0.5mg/kg/d; Leflunomide(lef);   D00749   1件: DHODH   1件: Pyrimidine metabolism   10件:
11,
40,
46,
49,
53,
66,
162,
224,
271,
300
 31   Loxoprofen  3件: Loxoprofen; Loxoprofen sodium hydrogel patch; Loxoprofen sodium tablet;   D08149   2件: PTGS1, PTGS2   1件: Arachidonic acid metabolism   2件:
46,
271
 32   Meloxicam  9件: Meloxicam; Meloxicam 0.125 mg/kg; Meloxicam 0.25 mg/kg; Meloxicam ampoule; Meloxicam cf tablet 7,5mg; Meloxicam oral suspension; Meloxicam tablet; Aspirin and meloxicam; Meloxicam suppository;   D00969   1件: PTGS2   1件: Arachidonic acid metabolism   4件:
46,
49,
271,
296
 33   Methotrexate  81件: Methotrexate; Intrathecal methotrexate; Methotrexate treatment; Mycophenolate mofetil,methotrexate; Methotrexate 2.5 mg; Methotrexate 25 mg; Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept + methotrexate; Adalimumab with methotrexate; Bms-582949 and methotrexate; Certolizumab pegol + methotrexate (mtx); Cp-690,550 + methotrexate; Etanercept + methotrexate; Etanercept , methotrexate; Infliximab + methotrexate (mtx); Infliximab, methylprednisolone, methotrexate; Methotrexate 'lederle' 2,5mg tablets; Methotrexate 'lederle' 2.5mg tablets; Methotrexate (metoject® prefilled pen); Methotrexate (mtx); Methotrexate + biologic administration; Methotrexate + infliximab; Methotrexate + methylprednisolone; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate - amneal; Methotrexate - dava; Methotrexate - delay; Methotrexate - etanercept - prednisolone arm; Methotrexate - immediate; Methotrexate 2.5 mg tablets; Methotrexate 2.5mg tablets; Methotrexate 2.5mg tablets bp; Methotrexate 50mg/ml solution for injection, pre-filled syringe; Methotrexate as methotrexate disodium; Methotrexate capsules; Methotrexate disodium; Methotrexate pfizer 2,5 mg tabletter; Methotrexate placebo; Methotrexate plus enbrel or enbrel alone; Methotrexate plus erb-041 for 12 weeks; Methotrexate plus sulfasalazine; Methotrexate pre-filled pen; Methotrexate prefilled pen; Methotrexate prefilled syringe; Methotrexate sodium; Methotrexate sodium 2.5mg tablets; Methotrexate sodium tablets 2.5 mg; Methotrexate(mtx); Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol.; Methotrexate(necessary); Methotrexate*100cpr 2,5mg; Methotrexate, leucovorin and bms-986142; Methotrexate,adalimumab; Methotrexate-lachema; Methotrexate-sulfasalazine-hydroxychloroquine; Methotrexate® 2.5 mg tablets; Mp-435(dose1) + methotrexate; Oral methotrexate; Phase 1: methotrexate; Response to anakinra associated with methotrexate; Response to infliximab associated with methotrexate; Stable weekly dose of methotrexate; Tacrolimus with methotrexate; Tasocitinib plus methotrexate; Tocilizumab + methotrexate(mtx); Tocilizumab+methotrexate(mtx); Tofacitinib with methotrexate; Tofacitinib without methotrexate; Urine samples taken to measure methotrexate and its major metabolite 7-oh-methotrexate level; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Methotrexate and folic acid; Methotrexate lachema 5inj. sol; Etanercept, methotrexate, prednisolone; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Azathioprine or methotrexate; Early immunosuppressants (azathioprine, methotrexate); Methotrexate bellon; Methotrexate bellon 25mg/ml; Clobetasol propionate + methotrexate; Treatment with systemic therapy (methotrexate); Cyclosporin, methotrexate (gvhd prophylaxis);   D00142
 D02115 
 2件: DHFR, DHFR2   2件: Folate biosynthesis, One carbon pool by folate   33件:
11,
13,
19,
34,
35,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
55,
56,
60,
62,
65,
84,
93,
96,
97,
162,
164,
172,
256,
271,
284,
285,
326,
331
 34   Methylprednisolone  29件: Methylprednisolone; Iv methylprednisolone; Iv methylprednisolone (steroids); Megadose oral methylprednisolone; Methylprednisolone (drug); Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Prednisone, methylprednisolone,cyclophosphamides; Methylprednisolone (or other glucocorticoid); Prednisone (and methylprednisolone); Infliximab, methylprednisolone, methotrexate; Methotrexate + methylprednisolone; Administration of rituximab and methylprednisolone; Methylprednisolone (mp); Corticosteroid treatment (methylprednisolone or prednisolone); Methylprednisolone or prednisolone; Methylprednisolone (mp) or prednisone (pred); Methylprednisolone mylan générique; Methylprednisolone pulse; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Methylprednisolone bolus iv 15 mg/kg/d for 3 days.; Methylprednisolone or budesonide; Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone; Intravenous methylprednisolone; Intravenous (i.v.) methylprednisolone 1000 mg, total 9;   D00407
 D00751
 D00979
 D05000
 D05001
 D05002 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   36件:
2,
13,
25,
26,
35,
38,
39,
40,
41,
42,
43,
45,
46,
49,
50,
51,
60,
63,
64,
65,
66,
83,
84,
86,
96,
97,
145,
164,
220,
222,
224,
271,
283,
284,
285,
296
 35   Misoprostol  1件: Misoprostol;   D00419   3件: PTGER2, PTGER3, PTGER4   3件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, cAMP signaling pathway   2件:
46,
271
 36   Naproxen  12件: Naproxen; Comparator: naproxen tablet 500 mg; Naproxen (ec-narosyn) delayed release tables, 375 (syntex (usa), inc.); Naproxen 10 mg/kg; Naproxen 500 mg tablets (pn 200 minus omeprazole); Naproxen delayed release tables, 375 (gevena pharmaceuticals, inc.); Naproxen oral suspension; Naproxen pch tablet 500mg; Naproxen sodium 550mg tablet; Pn 200 tablets (500 mg naproxen and 20 mg omeprazole); Part i- naproxen 1000 mg; Part ii- naproxen 1000 mg;   D00118   2件: PTGS1, PTGS2   1件: Arachidonic acid metabolism   3件:
13,
46,
271
 37   Olsalazine  1件: Olsalazine;   D00727
 D08295 
 -   -   1件:
271
 38   Omeprazole  19件: Clartihromycin, amoxicillin, and omeprazole; Esomeprazole; Omeprazole; Dimebon + omeprazole; Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Diclofenac + omeprazole; Esomeprazole 20 mg; Naproxen 500 mg tablets (pn 200 minus omeprazole); Pn 200 tablets (500 mg naproxen and 20 mg omeprazole); Omeprazole 20mg; Omeprazole (uk licensed generic product); Omeprazole 20 mg; Omeprazole 40 mg; Rifaximin+omeprazole+miralax; Omeprazole 20mg bid; Omeprazole magnesium; Omeprazole rectally 1mg/kg; Nexium (esomeprazole magnesium); Omeprazole 40mg capsule;   D00455
 D01207
 D05259
 D05261 
 2件: ATP4A, ATP4B   2件: Collecting duct acid secretion, Gastric acid secretion   15件:
6,
8,
13,
46,
51,
85,
96,
97,
98,
225,
271,
282,
294,
298,
299
 39   Pamidronic acid  0件:   D00941
 D07281 
 1件: FDPS   1件: Terpenoid backbone biosynthesis   2件:
271,
274
 40   Parecoxib  1件: Parecoxib;   D02709
 D03716 
 1件: PTGS2   1件: Arachidonic acid metabolism   2件:
46,
271
 41   Prednisolone  74件: Prednisolone; Iv methylprednisolone; Iv methylprednisolone (steroids); Megadose oral methylprednisolone; Methyloprednisolone; Methylprednisolone; Methylprednisolone (drug); Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Peg-liposomal prednisolone sodium phosphate; Prednisolone sodium phosphate; Prednisone/prednisolone; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Intravenous methyl prednisolone; Methyl prednisolone; Methylprednisolone (or other glucocorticoid); Prednisone (and methylprednisolone); Prednisone, methylprednisolone,cyclophosphamides; Infliximab, methylprednisolone, methotrexate; Long-circulating liposomal prednisolone; Methotrexate + methylprednisolone; Methotrexate - etanercept - prednisolone arm; Overencapsulated prednisolone tablets; Paroxetine & prednisolone; Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp; Prednisolone & dipyridamole; Prednisolone 20 mg; Prednisolone 40 mg; Prednisolone 5 mg; Prednisolone tablets bp; Prednisolone tablets usp 5 mg; Prednisolone-dipyridamole; Sulphasalazine + hydroxychloroquine or prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Z102 (prednisolone and dipyridamole).; Corticosteroids (prednisone or prednisolone); Oral prednisolone; Administration of rituximab and methylprednisolone; Prednisolone and taper; Etanercept, methotrexate, prednisolone; Methylprednisolone (mp); Prednisolone + mabthera; Corticosteroid treatment (methylprednisolone or prednisolone); Methylprednisolone or prednisolone; Methylprednisolone (mp) or prednisone (pred); Methylprednisolone mylan générique; Methylprednisolone pulse; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Prednisone or prednisolone; Azd4017 and prednisolone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Prednisolone 1mg tablets; Prednisolone 5mg tablet; Glucocorticoid (prednisone or prednisolone); Low dose prednisolone; Medium dose prednisolone; Methylprednisolone bolus iv 15 mg/kg/d for 3 days.; Corticosteroid (prednisolone); Prednisolone sodium succinate; Methylprednisolone or budesonide; Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone; Prednisolone sodium metasulphobenzoate; Prednisolone tablets b.p. 5mg; Intravenous methylprednisolone; Pyridoxine plus prednisolone; Soluble prednisolone tablets; Intravenous (i.v.) methylprednisolone 1000 mg, total 9; Prednisolone acetate; Prednisolone and chlorambucil; Prednisolone and mycophenolate mofetil;   D00472
 D00980
 D00981
 D00982
 D01239
 D01998
 D02156
 D03301 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   38件:
11,
13,
25,
26,
35,
38,
39,
41,
43,
44,
45,
46,
49,
50,
51,
56,
60,
61,
63,
64,
65,
66,
75,
81,
84,
85,
95,
96,
97,
113,
145,
162,
222,
269,
271,
296,
299,
300
 42   Propanoic acid  2件: (+)-(s)-2-(6-methoxynaphthalen-2-yl) propanoic acid; Propanoic acid;   D02310   -   -   1件:
271
 43   Rebamipide  1件: Rebamipide;   D01121   -   -   4件:
46,
53,
97,
271
 44   Risankizumab  4件: Risankizumab; Risankizumab iv; Risankizumab sc; Risankizumab (genetical recombination);   D11052   1件: IL23A   3件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Th17 cell differentiation   4件:
37,
96,
97,
271
 45   Rituximab  52件: Rituximab; Rituximab (rituxan); Mabthera (rituximab); Mabthera or biosimilar rituximab product; Rituximab infusion; Rituximab it; Rituximab iv; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Rituximab (mabthera® or rituxan®).; Rituximab and cyclophosphamide iv; Rituximab (arm a); Rituximab (arm b); Abatacept, rituximab or tocilizumab; Abp 798 - biosimilar to rituximab; Gp2013 - a proposed biosimilar rituximab; Idec-c2b8 (rituximab); Mabthera® (rituximab); Originator rituximab - rituxan ® or mabthera ®; Rituxan (inn: rituximab), brand name in the united states; Rituxan® (rituximab); Rituximab - mabthera; Rituximab [mabthera/rituxan]; Rituximab [mabthera]; Rituximab mabthera; Rituximab, mtx, folic acid; Rituximab, observational study amon patients with active ra; Rituximab-eu+ rituximab-pfizer x 2 courses; Rituximab-pfizer (pf-05280586) x 3 courses; Rituximab-us + rituximab-pfizer x 2 courses; Sait101 (proposed rituximab biosimilar); Individualized dose of rituximab; Rituxan (rituximab); Standard dose of rituximab; Administration of rituximab and methylprednisolone; Rituximab (anti-cd20); Alemtuzumab and rituximab; Bendamustine, rituximab; Mabthera or biosimilar rituximab; Rituximab (mabthera®); Alemtuzumab, rituximab; Dexamethasone and rituximab; Rhtpo in combination with rituximab; Immunosuppressive treatment (eg, rituximab); Rituximab (rtx) and azathioprine (aza); Intravenous rituximab; Combined plasma exchange (pex), rituximab, and corticosteroids; The standard steroid treatment, plasma exchange and rituximab; Rituximab 1g iv; Rituximab combined with omalizumab; Experimental (non immunosuppressive symptomatic treatment (nist) and rituximab); Rituximab/ mabthera; Rituximab or rituximab hyaluronidase human;   D02994   1件: MS4A1   1件: Hematopoietic cell lineage   42件:
11,
13,
14,
17,
35,
36,
43,
44,
45,
46,
49,
50,
51,
52,
53,
56,
60,
61,
63,
64,
65,
66,
83,
84,
85,
86,
93,
94,
96,
97,
162,
222,
223,
229,
256,
271,
283,
284,
285,
288,
300,
331
 46   Rosuvastatin  6件: Rosuvastatin; Rosuvastatin calcium; Calcium rosuvastatin; Crestor tablets (calcium rosuvastatin) film-coated tablets; Rosuvastatin 20mg; Rosuvastatin 10 mg;   D01915
 D08492 
 1件: HMGCR   1件: Terpenoid backbone biosynthesis   8件:
6,
46,
49,
51,
79,
96,
271,
299
 47   Sarilumab  4件: Sarilumab; Sarilumab sar153191; Sarilumab sar153191 (regn88); Sarilumab 200 mg/1.14 ml subcutaneous solution [kevzara]_#1;   D10161   1件: IL6R   2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway   5件:
41,
46,
84,
107,
271
 48   Secukinumab  12件: Secukinumab; Secukinumab 150mg; Secukinumab 300mg; Secukinumab 300 mg, s.c.; Secukinumab (ain457); 150 mg double-blinded secukinumab; 150 mg open-label secukinumab; 300 mg double-blinded secukinumab; Ain457/secukinumab; Secukinumab (150 mg); Secukinumab (75 mg); Secukinumab 150 milligram [cosentyx];   D09967   1件: IL17A   2件: Cytokine-cytokine receptor interaction, Rheumatoid arthritis   7件:
13,
37,
41,
46,
160,
269,
271
 49   Sulfasalazine  7件: Leflunomide-sulfasalazine-hydroxychloroquine; Methotrexate plus sulfasalazine; Methotrexate-sulfasalazine-hydroxychloroquine; Non-mtx dmards (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin); Sulfasalazine; Nsaids and sulfasalazine; Sulfasalazine, ssz;   D00448   -   -   3件:
46,
94,
271
 50   Thalidomide  9件: Thalidomide; Thalidomide (drug); Fpf 300 (thalidomide); Melphalan, thalidomide and dexamethasone; Thalidomide pharmion; Thalidomide celgene - 50 mg capsula rigida - uso orale - blister (pvc/pe/aclar/alu) 28 capsule; Thalidomide 100mg; Thalidomide 150mg; Thalidomide, cyclophosphamide and prednisone;   D00754   1件: TNF   4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, NF-kappa B signaling pathway, TNF signaling pathway   18件:
2,
16,
20,
28,
49,
51,
53,
65,
84,
85,
94,
96,
97,
227,
271,
280,
298,
331
 51   Tildrakizumab  4件: Tildrakizumab; Tildrakizumab 100 mg (one 1-ml injection of 100 mg/ml; Tildrakizumab 100 mg/ml; Tildrakizumab 200 mg (two 1-ml injections of 100 mg/ml);   D10400   1件: IL23A   1件: Cytokine-cytokine receptor interaction   1件:
271
 52   Tocilizumab  26件: Tocilizumab; Tocilizumab injection; Tocilizumab (mra-sc); Corticoids+ tocilizumab 8mg/kg/4 weeks; Tocilizumab + glucocorticoids (gcs); Tocilizumab sc; Tocilizumab treatment; Abatacept, rituximab or tocilizumab; Decrease tocilizumab, abatacept; Intra-articular tocilizumab; Mra (tocilizumab); Mra(tocilizumab); Subcutaneous tocilizumab; Tocilizumab (actemra®); Tocilizumab + methotrexate(mtx); Tocilizumab 162 mg; Tocilizumab 162mg/0.9ml jeringa sc; Tocilizumab [roactemra/actemra]; Tocilizumab [roactemra]; Tocilizumab prefilled syringe; Tocilizumab+methotrexate(mtx); Tocilizumab, abatacept; Tocilizumabum; Tocilizumab sc 162 mg/0.9 ml prefilled syringe with safety device (pfs); Inn-tocilizumab; Tocilizumab infusion roacemtra (eu);   D02596   1件: IL6R   3件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway   16件:
2,
13,
40,
41,
43,
46,
50,
51,
53,
54,
55,
86,
107,
266,
271,
331
 53   Tofacitinib  23件: Chong kun dang tofacitinib tablet; Cp-690,550 (tofacitinib); Tofacitinib; Tofacitinib (xeljanz); Tofacitinib 5 mg; Tofacitinib 5 mg [xeljanz]; Tofacitinib 5mg po bid; Tofacitinib citrate; Tofacitinib citrate (clinical trial image); Tofacitinib citrate (commercial image); Tofacitinib citrate cp-690550; Tofacitinib with methotrexate; Tofacitinib without methotrexate; Tofacitinib/baricitinib; Tofacitinib 5 mg twice daily; Tofacitinib 5mg [xeljanz] 1 year open-label extension; Tofacitinib 5mg oral tablet [xeljanz] 16 week trial; 15n2-tofacitinib; Tofacitinib citrate (proposed commercial formulation – debossed); In double-blind phase: treatment with tofacitinib; In open-label phase: treatment with tofacitinib; Tofacitinib 10 mg; Tofacitinib 2 mg;   D09970   4件: JAK1, JAK2, JAK3, TYK2   2件: Chemokine signaling pathway, JAK-STAT signaling pathway   9件:
46,
49,
50,
51,
84,
96,
97,
107,
271
 54   Tramadol  5件: Tramadol; Tramadol hydrochloride + acetaminophen; Amitriptyline, fluoxetine and tramadol alone (control group); Sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group); Tramadol /acetaminophen;   D01355
 D08623 
 1件: OPRM1   1件: Neuroactive ligand-receptor interaction   5件:
46,
70,
78,
226,
271
 55   Tripterygium wilfordii whole  0件:   -   -   -   8件:
46,
66,
67,
96,
162,
222,
224,
271
 56   Upadacitinib  2件: Upadacitinib; Upadacitinib (abt-494);   D10994   1件: JAK1   1件: JAK-STAT signaling pathway   6件:
41,
46,
49,
96,
97,
271
 57   Ustekinumab  32件: Ustekinumab; Prednisone and ustekinumab treatment; Ustekinumab (approximately 6 mg/kg); Ustekinumab 90 milligram (mg); Ustekinumab iv; Ustekinumab sc; Ustekinumab 6 mg/kg; Ustekinumab 90 mg; Subcutaneous ustekinumab; Stelara (ustekinumab); Ustekinumab liquid in prefilled syringe; Ustekinumab 180 mg; Ustekinumab 45 mg; Evaluation of biological predictive factors of clinical response to ustekinumab; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Placebo ustekinumab; Ustekinumab (6 mg/kg); Ustekinumab (90 mg); Ustekinumab 130 mg iv; Ustekinumab 1mg/kg (ip); Ustekinumab 3 mg/kg (ip); Ustekinumab 4.5 mg/kg; Ustekinumab 6 mg/kg (ip); Ustekinumab 90 mg (sc) group 1; Ustekinumab 90 mg (sc) group 2; Ustekinumab 90 mg sc q12w; Ustekinumab 90 mg sc q8w; Ustekinumab approximately 6 mg/kg (iv); Ustekinumab iv - nonresponder - ustekinumab 90mg sc (mp); Ustekinumab iv - responder - ustekinumab 90mg sc (mp); Ustekinumab iv infusion; Ustekinumab sc injection;   D09214   3件: IL12A, IL12B, IL23A   2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway   16件:
13,
37,
41,
46,
49,
50,
53,
56,
65,
84,
93,
96,
97,
162,
269,
271
 58   Water  13件: 5% glucose water solution; Water; Pseudoephedrine + 480 ml water; Pseudoephedrine + 50 ml water; 15 o water; Water for injection; 15-o labeled water; Pl 12185/0002 & pl 12185/0005(water for injection); Dextrose, 5% in water; High water intake; Lactose in water; Water for injections; Water for injections, ep;   D00001   -   -   22件:
2,
5,
6,
13,
17,
19,
28,
35,
46,
53,
57,
63,
65,
67,
78,
84,
97,
193,
226,
271,
278,
299
 59   Zoledronic acid  4件: Zoledronic acid; Zoledronic acid 5mg/bag 100ml inj; Zoledronic acid monohydrate; Lonafarnib, zoledronic acid, and pravastatin;   D01968
 D06378
 D06379
 D08689 
 1件: FDPS   1件: Terpenoid backbone biosynthesis   11件:
6,
13,
46,
65,
93,
95,
96,
271,
274,
299,
333

先頭へ